Goal II Phase II Studie zu Tafasitamab (MOR-208) bei rezidiviertem/refraktärem aggressivem Lymphom (Aktiv)
IPH4102-201 An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma (Aktiv)
MK7684A-004 Phase II Studie zu MK-7684A (Vibostolimab/Pembrolizumab) bei rezidivierenden/refraktären hämatologischen Krebserkrankungen (Aktiv)
Zuma I This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory aggressive Non-Hodgkin Lymphoma (NHL). (Aktiv)